Cannabis sativa is an Asian plant worldwide known as "marijuana", currently the drug most used among young and adults. It began to be studied from 1960, focusing on the compounds present in the drug, as well as its physiological effects. The use of its active constituents cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC) has been discussed by science due to its therapeutic properties in the fight against diseases such as anxiety, depression, epilepsy, and psychoses. Also, THC has analgesic effects and has been widely used in post-chemotherapy medicine, immunosuppressive diseases and marijuana use disorder. The purpose of this present review is to discuss and question the viability and efficacy of Delta-9-tetrahydrocannabinol (THC) against marijuana drug dependence observed in users. Its functionality is not known for sporadic users. The application for the treatment of addiction taking advantage of one of its most abundant components, the THC, allows the user not to experience severely symptoms of abstinence. There are recent studies using Delta-9-tetrahydrocannabinol to combat the overuse of marijuana, by giving serial doses of THC associated or not with drugs, in order to induce less harmful effects of "pleasure" and decrease the number of implications of smoking the herb itself. It is known that abstinence to Cannabis sativa is due to the cannabinoid THC because of its various connections to the central nervous system, however, it only presents such symptoms when it is in the body in a concentration between or greater than 80-210 mg per day, thus, the purpose of the studies is to obtain the ideal dose for the treatment of individuals seeking to quit the use disorder.